Financials in USD. Standardized financial statements.
A compact view of how G1 Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $82.51M | $51.30M | $31.48M | $45.28M | $0 | $0 | $0 | $0 | $522,000 | $1.04M |
| Revenue Growth? | +60.8% | +63.0% | -30.5% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | -49.9% | 0.0% |
| Cost of Revenue? | $7.20M | $3.75M | $2.02M | $0 | $356,000 | $175,000 | $89,000 | $67,226 | $12.73M | $5.02M |
| Gross Profit? | $75.32M | $47.55M | $29.46M | $45.28M | -$356,000 | -$175,000 | -$89,000 | -$67,226 | -$12.21M | -$3.98M |
| Gross Margin? | +91.3% | +92.7% | +93.6% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | -2338.7% | -381.4% |
| Operating Expenses? | $114.84M | $183.73M | $171.92M | $141.76M | $129.04M | $89.29M | $60.97M | $30.39M | $15.95M | $2.70M |
| Operating Income? | -$39.53M | -$136.18M | -$142.46M | -$96.48M | -$129.04M | -$89.29M | -$60.97M | -$30.39M | -$15.42M | -$6.68M |
| EBITDA? | -$34.30M | -$134.90M | -$142.46M | -$95.48M | $0 | $0 | $0 | -$30.32M | -$15.38M | -$6.66M |
| Income Before Tax | -$44.85M | -$145.86M | -$147.43M | -$97.84M | -$122.45M | -$85.29M | -$60.12M | -$30.29M | -$20.26M | -$6.68M |
| Income Tax Expense | $3.12M | $1.70M | $925,000 | $1.41M | -$356,000 | $0 | $41,000 | $82,231 | $4.86M | $502,364 |
| Net Income? | -$47.97M | -$147.56M | -$148.35M | -$99.25M | -$122.09M | -$85.29M | -$60.12M | -$30.29M | -$20.26M | -$7.18M |
| EPS? | $-0.93 | $-3.38 | $-3.54 | $-2.62 | $-3.26 | $-2.56 | $-2.08 | $-1.48 | $-0.99 | $-0.35 |
| Diluted EPS? | $-0.93 | $-3.38 | $-3.54 | $-2.62 | $-3.26 | $-2.56 | $-2.05 | $-1.48 | $-0.99 | $-0.35 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality